Teva Pharmaceutical Industries Ltd. (TEVA) reported $4.33 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 12.5%. EPS of $0.69 for the same period compares to $0.60 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $4.08 billion, representing a surprise of +6.12%. The company delivered an EPS surprise of +6.15%, with the consensus EPS estimate being $0.65.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Teva Pharmaceutical Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- International Markets: $613 million versus $615.37 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +26.4% change.
- Geographic Revenue- United States: $2.23 billion versus the four-analyst average estimate of $2.06 billion. The reported number represents a year-over-year change of +11.1%.
- Geographic Revenue- United States- COPAXONE: $69 million versus $49.93 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -33% change.
- Geographic Revenue- United States- BENDEKA / TREANDA: $40 million versus $38.21 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -29.8% change.
- Geographic Revenue- United States- AUSTEDO: $435 million versus the four-analyst average estimate of $436.83 million. The reported number represents a year-over-year change of +28.3%.
- Geographic Revenue- United States- Anda: $380 million versus the four-analyst average estimate of $351.57 million. The reported number represents a year-over-year change of +3.5%.
- Geographic Revenue- Europe- COPAXONE: $53 million versus the four-analyst average estimate of $47.56 million. The reported number represents a year-over-year change of -3.6%.
- Geographic Revenue- Europe- Respiratory products: $60 million versus the four-analyst average estimate of $57.37 million. The reported number represents a year-over-year change of -1.6%.
- Geographic Revenue- International Markets- Generic products: $477 million versus the four-analyst average estimate of $497.41 million. The reported number represents a year-over-year change of +25.2%.
- Geographic Revenue- International Markets- COPAXONE: $13 million versus $12.27 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +30% change.
- Geographic Revenue- United States- AJOVY: $58 million compared to the $56.34 million average estimate based on four analysts. The reported number represents a change of -4.9% year over year.
- Geographic Revenue- Europe- Generic products: $973 million versus the four-analyst average estimate of $930.59 million. The reported number represents a year-over-year change of +9.8%.
View all Key Company Metrics for Teva Pharmaceutical Industries here>>>
Shares of Teva Pharmaceutical Industries have returned +7.1% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。